Literature DB >> 20210798

Analysis of DOK-6 function in downstream signaling of RET in human neuroblastoma cells.

Ai Kurotsuchi1, Yoshiki Murakumo, Mayumi Jijiwa, Kei Kurokawa, Yasutomo Itoh, Yoshinori Kodama, Takuya Kato, Atsushi Enomoto, Naoya Asai, Hiroko Terasaki, Masahide Takahashi.   

Abstract

Point mutations and structural alterations of the RET tyrosine kinase gene cause multiple endocrine neoplasia type 2 (MEN 2) and papillary thyroid carcinoma, respectively. RET activation by glial cell line-derived neurotrophic factor (GDNF) is essential for the development of the enteric nervous system and the kidney. The signal through RET tyrosine kinase requires several adaptor proteins including the DOK (downstream of kinase) family of proteins. Of the seven members of the DOK protein family, DOK-1, -4, -5, and -6 have been reported to play roles in the GDNF-RET signaling pathway. Although DOK-6 has been shown to bind to RET and promote GDNF-induced neurite outgrowth in mouse Neuro2A cells, DOK-6 function in human cells remains unclear. In the present study, we investigated the role of DOK-6 in GDNF-RET signaling in human cells including neuroblastoma cells. DOK-6 was constitutively localized to the plasma membrane via its pleckstrin homology (PH) domain, and was phosphorylated following RET activation via a MEN2A mutation or GDNF stimulation. However, DOK-6 could not significantly affect downstream signaling and neurite outgrowth in human neuroblastoma cells. The binding affinity of the DOK-6 phosphotyrosine-binding (PTB) domain to RET was much lower than that of the DOK-1, DOK-4, and SHC PTB domains to RET. These findings indicate that DOK-6 is involved in RET signaling with less influence when compared with DOK-1, DOK-4, and SHC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20210798     DOI: 10.1111/j.1349-7006.2010.01520.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

Review 1.  The Emerging Portrait of Glial Cell Line-derived Neurotrophic Factor Family Receptor Alpha (GFRα) in Cancers.

Authors:  Qingshang Li; Zhijun Cao; Shuliang Zhao
Journal:  Int J Med Sci       Date:  2022-03-28       Impact factor: 3.642

Review 2.  Structure and physiology of the RET receptor tyrosine kinase.

Authors:  Carlos F Ibáñez
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

3.  mRNA expression of DOK1-6 in human breast cancer.

Authors:  Tamara Ghanem; James Bracken; Abdul Kasem; Wen G Jiang; Kefah Mokbel
Journal:  World J Clin Oncol       Date:  2014-05-10

Review 4.  Multiple endocrine neoplasias type 2B and RET proto-oncogene.

Authors:  Giuseppe Martucciello; Margherita Lerone; Lara Bricco; Gian Paolo Tonini; Laura Lombardi; Carmine G Del Rossi; Sergio Bernasconi
Journal:  Ital J Pediatr       Date:  2012-03-19       Impact factor: 2.638

5.  Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival.

Authors:  Siew Hong Leong; Kyaw Myo Lwin; Sze Sing Lee; Wai Har Ng; Kia Min Ng; Soo Yong Tan; Bee Ling Ng; Nigel P Carter; Carol Tang; Oi Lian Kon
Journal:  NPJ Precis Oncol       Date:  2017-05-01

6.  DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.

Authors:  Guo-Kang Sun; Li-Juan Tang; Jing-Dong Zhou; Zi-Jun Xu; Lan Yang; Qian Yuan; Ji-Chun Ma; Xing-Hui Liu; Jiang Lin; Jun Qian; Dong-Ming Yao
Journal:  Cancer Med       Date:  2019-09-04       Impact factor: 4.452

7.  Association between ABHD1 and DOK6 polymorphisms and susceptibility to Hirschsprung disease in Southern Chinese children.

Authors:  Chaoting Lan; Yuxin Wu; Ning Wang; Yun Luo; Jinglu Zhao; Yi Zheng; Yan Zhang; Lihua Huang; Yun Zhu; Lifeng Lu; Wei Zhong; Jixiao Zeng; Huimin Xia
Journal:  J Cell Mol Med       Date:  2021-09-20       Impact factor: 5.310

Review 8.  The GDNF Family: A Role in Cancer?

Authors:  Graeme C Fielder; Teresa Wen-Shan Yang; Mahalakshmi Razdan; Yan Li; Jun Lu; Jo K Perry; Peter E Lobie; Dong-Xu Liu
Journal:  Neoplasia       Date:  2017-12-12       Impact factor: 5.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.